Allarity Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Allarity Therapeutics's earnings are forecast to decline at 10.2% per annum while its annual revenue is expected to grow at 115.8% per year. EPS is expected to grow by 31% per annum.

Wichtige Informationen

-10.2%

Wachstumsrate der Gewinne

31.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.1%
Wachstumsrate der Einnahmen	115.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	02 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ALLR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-33	N/A	N/A	1
12/31/2025	N/A	-29	N/A	N/A	1
12/31/2024	N/A	-16	N/A	N/A	1
6/30/2024	N/A	-13	-16	-16	N/A
3/31/2024	N/A	-21	-11	-11	N/A
12/31/2023	N/A	-20	-13	-13	N/A
9/30/2023	N/A	-22	-14	-14	N/A
6/30/2023	N/A	-23	-13	-13	N/A
3/31/2023	N/A	-20	-14	-14	N/A
12/31/2022	N/A	-21	-17	-17	N/A
9/30/2022	N/A	-35	-19	-19	N/A
6/30/2022	N/A	-29	-18	-18	N/A
3/31/2022	N/A	-28	-18	-18	N/A
12/31/2021	N/A	-27	-15	-15	N/A
9/30/2021	-1	-12	-13	-13	N/A
6/30/2021	-1	-12	-11	-11	N/A
3/31/2021	N/A	-7	-8	-8	N/A
12/31/2020	N/A	-7	-7	-7	N/A
9/30/2020	1	-16	-7	-7	N/A
6/30/2020	1	-17	-8	-8	N/A
3/31/2020	0	-20	-10	-10	N/A
12/31/2019	0	-20	-11	-11	N/A
9/30/2019	0	-11	-11	-10	N/A
6/30/2019	1	-8	-9	-9	N/A
3/31/2019	1	-4	-7	-6	N/A
12/31/2018	1	-2	-4	-4	N/A
9/30/2018	2	-1	-2	-2	N/A
6/30/2018	1	-1	-2	-2	N/A
3/31/2018	2	-4	N/A	0	N/A
12/31/2017	1	-5	N/A	-1	N/A
9/30/2017	1	-6	N/A	-3	N/A
6/30/2017	1	-6	N/A	-3	N/A
3/31/2017	0	-4	N/A	-5	N/A
12/31/2016	0	-4	N/A	-4	N/A
9/30/2016	1	-3	N/A	-4	N/A
6/30/2016	1	-2	N/A	-4	N/A
3/31/2016	1	-2	N/A	-3	N/A
12/31/2015	0	-1	N/A	-2	N/A
12/31/2014	0	0	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALLR is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: ALLR is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: ALLR is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: ALLR is forecast to have no revenue next year.

Hohe Wachstumseinnahmen: ALLR is forecast to have no revenue next year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if ALLR's Return on Equity is forecast to be high in 3 years time

Allarity Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics, Inc. Announces Management Appointments

Holzer & Holzer, LLC Announces Class Action Lawsuit on Behalf of Allarity Therapeutics, Inc

Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million.

Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding

Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic

Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff

Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology

Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients

Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP

Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price

Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study

Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

High number of new and inexperienced directors

Allarity Therapeutics Receives Notice from the Nasdaq

Allarity Therapeutics Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics GAAP EPS of -$0.72 misses by $0.46

Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics GAAP EPS of -$0.52 misses by $0.07

Allarity Therapeutics, Inc., Annual General Meeting, Nov 04, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors

Allarity Therapeutics, Inc. Announces Executive Leadership Transition

Allarity Therapeutics appoints interim CEO, CFO

Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board

Allarity Therapeutics, Inc. Announces Impairment for the First Quarter Ended March 31, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc. announced delayed annual 10-K filing

Allarity Therapeutics, Inc. Receives Refusal to File Letters from U.S. FDA

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken